Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Blast Crisis 1

Interventions

Peripheral Blood Stem Cell Transplantation 10fludarabine phosphate 9Cyclophosphamide 9Filgrastim 8Busulfan 8Interferon-alpha 7Cytarabine 7Antilymphocyte Serum 7Radiotherapy 6Imatinib Mesylate 6Cyclosporine 6sargramostim 4Methylprednisolone 4Methotrexate 4Etoposide 4Tacrolimus 3Mycophenolic Acid 3Idarubicin 3Hydroxyurea 3Homoharringtonine 3Sunitinib 2Melphalan 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dasatinib 2Carboplatin 2Analgesia 2tipifarnib 1temsirolimus 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Chronic-Phase × danusertib × Clear all
NCT00335868 2013-12-18

PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

National Cancer Institute (NCI)

Phase 2 Unknown
16 enrolled
Other hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡